Major Depressive Disorder Clinical Trial
Official title:
Narrative Intervention to Disseminate ACT for Depression in Primary Care
The overall aim of this program of research is to develop a collaborative narrative
intervention for patients with depression being treated in primary care.
The purpose of the proposed project is to establish the feasibility, acceptability, and
preliminary effects of our newly developed narrative intervention on depression.
To achieve the specific aims, the investigators will conduct an open trial to further develop
and refine the intervention (n = 10).
The public health impact of existing treatments for major depression is limited by our
ability to disseminate those treatments. There is a particular need to find innovative ways
to disseminate key principles of empirically supported psychotherapy in primary care
settings. Narrative communication is an alternative way to disseminate psychotherapy behavior
change principles. Narrative communication refers to "storytelling" -real people talking
about their struggles and successful ways of coping. An advantage of narrative communication
is that it can be easily distributed (by video) and may reach people who do not have access
to other technologies or who experience barriers to traditional psychotherapy. We propose
that key principles of a type of cognitive-behavioral therapy (Acceptance and Commitment
Therapy, or ACT) can be readily disseminated through a video storytelling intervention. ACT
is an empirically supported therapy for depression. Together with a video production firm
with a record of working in healthcare and developing documentary-style videos, we will
produce a storytelling video intervention (sTVi).
Our aim is to conduct a small open trial (n = 10) of antidepressant medication treatment as
usual + sTVi. Assessments will occur at baseline and 4 weeks (post-treatment). We will
examine the feasibility and acceptability of sTVi (e.g., uptake and completion of sTVi,
engagement with videos, and understanding of key ACT principles) and of this research design.
We will examine treatment effects (within relevant confidence intervals) on outcomes (e.g.,
depression severity). We will examine change in potential mechanisms, i.e., ACT-consistent
coping strategies derived from key ACT principles.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |